4Delmas PD,5 Schlemmer A,Gineyts E,et al.Urinary excretion of pyridinoline cross-links correlate with bone turn over measured on iliocrsest bone biopsy in patients with vertebral osteoporosis[J].J Bone Miner Res,1991,6(1):639～644.
6JJ.Body.Metastic Bone Disease:Clinical and Therapeutic Aspects.Bone,1992,3,S57-S62Paterson AHG.Bone metastases in breast cancer,prostate cancer and myeloma[J].Bone,1987,8(suppl 1):17～22.
7Coleman RE,Mashiter G,Whitaker KB,et al.Bone scan flare predict successful systemic therapy for bone metastases [J].Med J Nucl,1988,29(8):1354～1359.
8Lipton A,Costa L,Ail S,et al.Use of Bone Turnover for Monitoring Bone Metastases and the Respone to Therapy [J].Semin Oncol,2001,28(4 Suppl 11):54～59.
9Miyamoto KK,McSherry SA,Robins SP,et al.Collagen crosslink metabolites in urine as markers of bone metastases in prostatic carcinoma[J].J Urol,1994,151(4):909～913.
10Demers LM,Costa L,Chinchilli VM,et al.Biochemical markers of bone turnover in patients with metastatic bone disease[J].GlinChem,1995,41(10):1489～1494.
二级参考文献9
11，Elomaa I,Blomqvist C,Grohn P,et al: Long－ term controlled trial of bisphosphonate in－ patients with osteolytic bone metastases. Lancet1:1983;146～ 9
22，Diel I,Solomayer E－ F,Goerner R,et al. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non－ bone metastases.Proc Am Soc Clin Oncol,1997(Abstr);16:130
33，Delmas PD,Schlemmer A,Gineyts E, et al. Urinary excretion ofpyridinoline cross－ links correlate with bone turn over measured on iliocrest bone biopsy in patients with vertebral osteoporosis. J Bone Miner Res, 1991;6:639～ 4
44，Delmas PD.Biochemical markers of bone turn over for the clinical assess of metabolic bone disease.Endocrinol. Metab Clin North Am,1990;19:1～ 18
55，Body JJ,Dumon JC,Piccart M,and et al. Intravenous pamidronate in－ patients with tumor induced osteolysis:a biochemical dose－ response study. J Bone Miner Res.1995;10:1191～ 6
66，Coleman RE,Mashiter G,Whitaker KB,et al. Bone scan flare predict ssuccessful systemic therapy for bone metastases.Med,1988;29(8):1355～ 9
77，Harris ST,Gertz BJ,Genant HK,et al. The effect of short－ term treatment with alendronate on vertebral density and biochemical markers of bones remodeling in early postmenopausal women. J Clin Endocrinol Metab.1993;76:1399～ 406
88，Body JJ,Dumon JC,Gineyts E,et al. Comparative evaluation of markers of bone resorption patients with breast cancer－induced osteolysis before and after bisphosphonate therapy. Br J Cancer,1997;75(3):408～ 12
99，Launence M,Demers,Luis Costa,et al. Biochemical markers of bone turn over in patients with metastatic bone disease.Clin
